Trial Profile
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Lulizumab pegol (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 02 Jan 2019 Status changed to completed.
- 10 Nov 2018 Primary endpoint has not been met. (Proportion of subjects who achieve a BICLA response (BICLA response rate))
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting